查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918170

智慧避孕药市场在生育治疗领域的预测（2026-2031）

Smart Pills in Fertility Treatment Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计用于不孕症治疗的智慧药丸市场将以 7.57% 的复合年增长率增长，到 2025 年达到 1,032,874,000 美元，到 2031 年达到 1,599,917,000 美元。

生育智能药丸市场是一个新兴但极具创新性的领域，它融合了数位健康、感测器技术和生殖医学。这个新兴领域致力于开发可吞嚥的感测器系统（通常由药丸大小的设备与外部接收器组成），旨在监测与不孕症相关的关键生理参数。虽然用于胃肠道成像的传统「智慧药丸」概念已较为成熟，但其在生育治疗领域的应用仍处于设想阶段，可能侧重于基础体温、激素代谢物追踪或其他与月经週期和排卵相关的生物标记。该市场提案突破间歇性门诊就诊和主观症状追踪的局限，提供持续、客观的数据，从而实现更精准、个人化和数据驱动的生育治疗管理。

关键市场驱动因素与价值提案

推动这一潜在市场发展的核心因素是对不孕症治疗日益个人化和精准化的迫切需求。生育治疗结果差异很大，且受个体微妙的荷尔蒙节律和生理状态的影响。目前的通讯协定通常依赖基于人群平均值的标准化荷尔蒙疗法和用药时间。而能够提供即时、个人化生物回馈疗法的技术，可以动态调整药物剂量，并优化子宫内人工授精（IUI）和体外受精（IVF）卵子等操作的时间。这种从静态治疗模式转向自适应治疗模式的转变，可望提高治疗週期的成功率，并减轻多次治疗试验带来的身心负担。

这与提高患者参与度和依从性，从而更好地执行复杂繁琐的治疗通讯协定的目标直接契合。生育治疗需要严格的用药计画、频繁的追踪监测、精准的介入时机。智慧药丸技术透过自动采集关键参数数据，简化了患者的参与流程，并有可能减少仅用于监测的抽血和超音波次数。透过在患者和医疗专业人员之间共用清晰、连续的资料流，这些系统可以促进更协作的管理模式，从而提高治疗依从性并减轻患者的焦虑。

整个医疗领域向数位化医疗和远端患者监护的广泛发展趋势，正在创造一个有利于这些创新的环境。穿戴式装置和健康应用程式的普及，使患者和医疗服务提供者都习惯了以数据为中心的医疗服务。将口服型感测器整合到综合生育管理平台中，是这一趋势的自然延伸，与药物管理应用程式、症状追踪应用程式和医疗服务提供者沟通工具相辅相成。这与去中心化临床试验和远端医疗的发展趋势相吻合，这些趋势正在迅速发展，并有可能实现更便捷的生育照护。

此外，全球不孕症盛行率持续居高不下且不断攀升，凸显了开发更有效解决方案的迫切需求。众多夫妇面临受孕困难，因此，能够显着提高辅助生殖技术（ART）效率和成功率的技术拥有巨大的潜在市场。任何能够提高每个治疗週期活产率的工具，都满足了重要的临床和经济需求。

市场演变与策略考量

必须认识到，该市场目前主要处于概念和早期发展阶段。将口服型感测器技术应用于特定生育领域面临独特的技术和临床挑战，包括：

  • 生物标记识别和感测器设计：识别胃肠道中与即时生殖状态准确相关的、一致且可测量的生物标记（例如，特定的荷尔蒙代谢物），然后设计稳健的微型感测器来检测这些生物标记。
  • 临床检验：透过严格的临床试验，我们证明所提供的数据可以转化为可操作的临床决策，与标准监测相比，这些决策可以实际改善临床怀孕率和活产率等结果。
  • 监管：成功地应对复杂的监管环境，作为组合产品（药物/医疗设备或生物製药/医疗设备），与FDA和EMA等监管机构打交道。
  • 成本效益和报销：建立令人信服的健康经济学原理，以证明在已经很昂贵的生育治疗週期中这项技术的额外成本是合理的，并确保获得报销。

地理视角

如果这些产品最终上市，北美预计将成为其研发和推广的早期重点区域。该地区聚集了众多生物技术和数位医疗Start-Ups，并拥有大量用于医疗技术创新的创业投资投资。此外，北美还拥有庞大且成熟的生育诊所生态系统，以及完善的法规结构（透过美国食品药物管理局 (FDA)），为新型数位医疗工具的推广应用提供了便利。美国生育治疗的高昂自付费用也可能催生一个对高附加价值高端技术持开放态度的市场。

欧洲拥有先进的医疗保健体系和强大的研究机构，将成为临床研究和实施的关键地区，尤其是在获得有利的卫生技术评估（HTA）结果支持的情况下。亚太地区人口众多，对生育治疗服务的需求不断增长，蕴藏着巨大的长期机会，但相关技术的实施可能只有在西方市场验证后才会进行。

总之，生育智能药丸市场展现了精准生殖医学未来令人瞩目的发展前景。其成长潜力源自于两大强劲因素的融合：生育治疗领域尚未满足的临床需求以及数位健康监测技术的进步。然而，克服重大的科学、监管和经济障碍是实现这一潜力的关键。相关人员的未来发展方向在于：进行针对性研发，以解决特定的生物标记检测难题；建立感测器技术公司与生育领域的製药和临床领导企业之间的策略联盟；以及产生确凿的临床证据，证明其能够带来更优的患者疗效。如果成功，这项技术有望将生育治疗从间歇性的、以诊所为中心的模式转变为持续性的、以患者为中心、数据优化的流程。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探索推动市场的动态因素和关键趋势，以及它们将如何塑造未来的市场发展。
  • 可操作的建议：利用这些见解，在快速变化的环境中製定策略决策，发展新的商业机会和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

以下是一些公司如何使用这份报告的范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

第五章 智慧避孕药市场（按类型划分）

  • 介绍
  • 智慧胶囊
  • 智慧型平板电脑
  • 内建感应器的智慧药丸

第六章 按应用领域分類的生育治疗智慧药丸市场

  • 介绍
  • 排卵追踪
  • 荷尔蒙监测
  • 生育药物管理
  • 卵子品质评估
  • 其他的

第七章 最终使用者在生育治疗领域的智慧药丸市场

  • 介绍
  • 不孕症治疗诊所/中心
  • 医院和诊所
  • 研究所
  • 妇科诊所
  • 其他的

第八章 各地区生育治疗智能药丸市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十章：公司简介

  • Proteus Digital Health, Inc.
  • Adherium Limited
  • Bayer Ag
  • The Cooper Companies, Inc.
  • Medicom Innovation Partner A/S
  • Quotient Limited
  • Medtronic Plc
  • Microchips Biotech, Inc.
  • Elfi-Tech Ltd.
  • Ferring Pharmaceuticals

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061616643

Smart Pills In Fertility Treatment Market is projected to grow at a 7.57% CAGR, reaching USD 1,032.874 million in 2025 to USD 1599.917 million in 2031.

The smart pills in fertility treatment market represents a nascent but highly innovative convergence of digital health, sensor technology, and reproductive medicine. This emerging segment involves the development of ingestible sensor systems-often comprising a pill-sized device and a paired external receiver-designed to monitor key physiological parameters relevant to fertility. While the classic "smart pill" concept for gastrointestinal imaging is more established, its application in fertility is more speculative and forward-looking, potentially focusing on core body temperature, hormone metabolite tracking, or other biomarkers linked to the menstrual cycle and ovulation. The market proposition centers on moving beyond intermittent clinic visits and subjective symptom tracking to provide continuous, objective data, thereby enabling a more precise, personalized, and data-driven approach to fertility management.

Primary Market Drivers and Value Proposition

The central driver for this potential market is the pressing need for enhanced personalization and precision in fertility care. Fertility treatment outcomes are highly variable and influenced by subtle, individual hormonal rhythms and physiological states. Current protocols often rely on standardized hormone regimens and timing based on population averages. A technology capable of providing real-time, personalized biofeedback could allow for dynamic adjustment of medication dosages and optimal timing for procedures like intrauterine insemination (IUI) or oocyte retrieval for in vitro fertilization (IVF). This shift from a static to an adaptive treatment model holds the promise of improving cycle success rates and reducing the physical and emotional burden of multiple treatment attempts.

This is directly linked to the goal of improving patient engagement and adherence within often complex and demanding treatment protocols. Fertility treatments require strict adherence to medication schedules, frequent monitoring appointments, and precise timing of interventions. Smart pill technology could simplify patient involvement by automating data collection on critical parameters, reducing the need for some clinic visits for blood draws or ultrasounds solely for monitoring. By giving patients and clinicians shared access to clear, continuous data streams, these systems could foster a more collaborative management approach, potentially increasing treatment compliance and reducing anxiety.

The broader trend toward digital health and remote patient monitoring across all medical specialties creates a receptive environment for such innovation. The proliferation of wearable devices and health apps has accustomed both patients and providers to data-centric care. Integrating an ingestible sensor into a comprehensive fertility management platform-alongside apps for medication tracking, symptom logging, and provider communication-represents a logical extension of this trend. It aligns with the movement toward decentralized clinical trials and telehealth, which gained significant momentum and could be leveraged for more convenient fertility care.

Furthermore, the persistently high and growing global prevalence of infertility underscores the need for more effective solutions. With a significant portion of couples experiencing difficulty conceiving, there is a substantial addressable market for technologies that can demonstrably improve the efficiency and success of assisted reproductive technologies (ART). Any tool that can increase live birth rates per treatment cycle addresses a profound clinical and economic need.

Market Evolution and Strategic Considerations

It is critical to recognize that this market is primarily in a conceptual and early development stage. The translation of ingestible sensor technology to fertility-specific applications presents distinct technical and clinical challenges. These include:

  • Biomarker Identification & Sensor Design: Identifying a consistent, measurable biomarker within the gastrointestinal tract that accurately correlates with real-time fertility status (e.g., specific hormone metabolites) and designing a robust, miniaturized sensor for it.
  • Clinical Validation: Demonstrating through rigorous clinical trials that the data provided leads to actionable clinical decisions that tangibly improve outcomes such as clinical pregnancy rates or live birth rates, compared to standard monitoring.
  • Regulatory Pathway: Navigating the complex regulatory landscape as a combination product (drug/device or biologic/device) with agencies like the FDA and EMA.
  • Cost-Effectiveness & Reimbursement: Establishing a compelling health economic argument to justify the additional cost of the technology within already expensive fertility treatment cycles, and securing insurance reimbursement.

Geographical Outlook

North America is anticipated to be the initial focal point for development and potential adoption, should such products reach market. The region possesses a concentration of biotechnology and digital health startups, significant venture capital funding for medtech innovation, a large and established fertility clinic ecosystem, and a regulatory framework (through the FDA) that has pathways for novel digital health tools. High patient out-of-pocket spending on fertility treatments in the U.S. also creates a market potentially willing to adopt premium, value-added technologies.

Europe, with its advanced healthcare systems and strong research institutions, would also be a key region for clinical research and adoption, particularly if supported by positive health technology assessment outcomes. The Asia-Pacific region, with its large population and growing demand for fertility services, represents a major long-term opportunity but would likely follow after validation in Western markets.

In conclusion, the smart pills in fertility treatment market embodies a compelling vision for the future of precision reproductive medicine. Its potential growth is driven by the powerful convergence of unmet clinical needs in fertility and the advancing frontier of digital health monitoring. Realizing this potential, however, is contingent upon overcoming significant scientific, regulatory, and economic hurdles. For stakeholders, the path forward involves targeted R&D to solve specific biomarker sensing challenges, strategic partnerships between sensor technology companies and fertility pharmaceutical/clinical leaders, and a focus on generating definitive clinical evidence of superior patient outcomes. If successful, such technology could indeed transform fertility care from an episodic, clinic-centric model to a continuous, patient-empowered, and data-optimized journey.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Smart Pills in Fertility Treatment Market Segmentation

  • By Type
  • Smart Capsules
  • Smart Tablets
  • Smart Pills With Embedded Sensors
  • By Application
  • Ovulation Tracking
  • Hormone Monitoring
  • Fertility Medication Management
  • Egg Quality Assessment
  • Others
  • By End-User
  • Fertility Clinics And Centers
  • Hospitals And Clinics
  • Research Institutions
  • Women's Health Clinics
  • Others
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SMART PILLS IN FERTILITY TREATMENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Smart Capsules
  • 5.3. Smart Tablets
  • 5.4. Smart Pills With Embedded Sensors

6. SMART PILLS IN FERTILITY TREATMENT MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Ovulation Tracking
  • 6.3. Hormone Monitoring
  • 6.4. Fertility Medication Management
  • 6.5. Egg Quality Assessment
  • 6.6. Others

7. SMART PILLS IN FERTILITY TREATMENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Fertility Clinics And Centers
  • 7.3. Hospitals And Clinics
  • 7.4. Research Institutions
  • 7.5. Women's Health Clinics
  • 7.6. Others

8. SMART PILLS IN FERTILITY TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Proteus Digital Health, Inc.
  • 10.2. Adherium Limited
  • 10.3. Bayer Ag
  • 10.4. The Cooper Companies, Inc.
  • 10.5. Medicom Innovation Partner A/S
  • 10.6. Quotient Limited
  • 10.7. Medtronic Plc
  • 10.8. Microchips Biotech, Inc.
  • 10.9. Elfi-Tech Ltd.
  • 10.10. Ferring Pharmaceuticals

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations